Long-term effects of levonorgestrel-releasing intrauterine system on tamoxifen-treated breast cancer patients: A meta-analysis

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 10, 2014, Pages 6419-6429

  Fu, Yun ^a   Zhuang, Zhigang ^a  

^a Shanghai First Maternity and Infant Health Hospital   (China)

Author keywords

Breast cancer; Endometrial lesion; LNG IUS; Tamoxifen

Indexed keywords

ANTIESTROGEN; LEVONORGESTREL; TAMOXIFEN;

BREAST NEOPLASMS; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; META ANALYSIS; MORTALITY; PATHOLOGY; POLYPS; RISK; RISK FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; POLYPS; RISK FACTORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84912075615     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-518.
2. Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel) 2011; 6: 136-141.
3. Santen RJ. Clinical review: Effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab 2011; 96: 308-319.
4. Cole LK, Jacobs RL, Vance DE. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 2010; 52: 1258-1265.
5. Otsuka I, Takahashi S, O'Uchi K, Akimoto N, Hanari K, Ogaki Y, Enatsu YH, Takigawa A, Takaya H, Tanaka A Kaseki H, Yamada T. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients]. Gan Kagaku Ryoho 2010; 37: 279-283.
6. Leung F, Terzibachian JJ, Govyadovskiy A, Bourtembourg A, Maillet R, Riethmuller D. [Tamoxifen in the adjuvant setting for breast cancer: Reflexions about the risk of uterine carcinosarcoma]. Gynecol Obstet Fertil 2009; 37: 447-451.
7. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
9. Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, Habiba M. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecol Oncol 2009; 114: 452-456.
10. Wong AW, Chan SS, Yeo W, Yu MY, Tam WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol 2013; 121: 943-950.
11. Kesim MD, Aydin Y, Atis A, Mandiraci G. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 2008; 11: 252-257.
12. Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, Wong AW, Kwan WH, Yuen PM. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 2007; 114: 1510-1515.
13. Gardner FJ, Konje JC, Abrams KR, Brown LJ, Khanna S, Al-Azzawi F, Bell SC, Taylor DJ. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000; 356: 1711-1717.
14. Perlman S, Vaisbuch E, Ben-Arie A. [Tamoxifen treatment and malignant endometrial tumors--what's new?]. Harefuah 2006; 145: 219-222, 244.
15. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol 2006; 107: 1475-1478.
16. Daniel Y, Inbar M, Bar-Am A, Peyser MR, Lessing JB. The effects of tamoxifen treatment on the endometrium. Fertil Steril 1996; 65: 1083-1089.
17. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metabo 2011; 22: 145-152.
18. Powles TJ, Bourne T, Athanasiou S, Chang J, Grubock K, Ashley S, Oakes L, Tidy A, Davey J, Viggers J, Humphries S, Collins W. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo. Br J Cancer 1998; 78: 272-275.
19. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI. Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J (Clin Res Ed) 1983; 287: 1241-1245.
20. Haimovich S, Checa MA, Mancebo G, Fuste P, Carreras R. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device. Menopause 2008; 15: 1002-1004.
21. Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). Acta Obstet Gynecol Scand 2012; 91: 3-9.
22. Wildemeersch D, Pylyser K, De Wever N, Pauwels P, Tjalma W. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution. Maturitas 2007; 57: 205-209.
23. Hampton NR, Rees MC, Lowe DG, Rauramo I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005; 20: 2653-2660.
24. Wan YL, Holland C. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. Climacteric 2011; 14: 622-632.
25. Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A, Koskenvuo M. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005; 106: 813-817.
26. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 2008; 90: 17-22.